NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. have announced an agreement on the sale and marketing of Avenova® brand products of the Sonoma company in the European Union. The new products will combine Sonoma’s existing ophthalmic product, Ocudox®?, already Class IIB CE marked for sale in the European Union, with the Avenova brand, and are expected to be marketed through Sonoma’s established European distribution network. This agreement brings together NovaBay’s extensive knowledge of eye care, reflected in its Avenova brand, and Sonoma’s expertise in the international distribution of hypochlorous acid products.
Sonoma will manufacture Avenova’s Ocudox in packaging similar to Avenova’s NovaBay products, which are the leading hypochlorous acid eye care products in the United States. Sonoma will pay NovaBay a royalty based on Avenova’s net sales of Ocudox, and Sonoma will continue to market its Ocudox product in the European Union.